Patents Assigned to Roslin Institute
  • Publication number: 20060105323
    Abstract: A system for the detection of gene activation events is provided which comprises a nucleic acid construct encoding a protein of the lipocalin protein family and a peptide tag in which the expression of the construct in a cell or in the cells of a transgenic animal demonstrates the activation of a gene or genes of interest, in which the protein expressed is secreted from the cell and in which detection of the peptide tag indicates expression of the construct.
    Type: Application
    Filed: July 25, 2003
    Publication date: May 18, 2006
    Applicant: Roslin Institute (Edinburgh) Biosciences Ltd.
    Inventors: Christopher Whitelaw, Anthony Clark, Helen Clark, Wolf Charles Roland
  • Publication number: 20060051813
    Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.
    Type: Application
    Filed: July 1, 2005
    Publication date: March 9, 2006
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Michael Clinton, Gino Miele, Jean Manson
  • Patent number: 6962787
    Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: November 8, 2005
    Assignee: Roslin Institute (Edinburgh)
    Inventors: Michael Clinton, Gino Miele, Jean Catherine Manson
  • Patent number: 6921665
    Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: July 26, 2005
    Assignees: Roslin Institute (Edinburgh), Geron Corporation
    Inventors: Jim McWhir, Joseph D. Gold, J. Michael Schiff
  • Publication number: 20030186437
    Abstract: A method of controlling the differentiation of a cell is provided which comprises modulation of the expression of the gene Raidd in the cell. The method provides a means for preparing or enriching a population of stem cells through modulation of Raidd expression.
    Type: Application
    Filed: March 29, 2002
    Publication date: October 2, 2003
    Applicant: ROSLIN INSTITUTE
    Inventors: Anthony John Clark, Ricardo Felmer, Simon Horvat
  • Publication number: 20030106081
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: September 5, 2002
    Publication date: June 5, 2003
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Publication number: 20030101468
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: July 9, 2002
    Publication date: May 29, 2003
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Patent number: 6525243
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: February 25, 2003
    Assignees: Roslin Institute, The Minister of Agricultural, Fisheries and Food, Biotechnology & Biological Sciences Research Council
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Publication number: 20030037352
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: October 11, 2001
    Publication date: February 20, 2003
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Publication number: 20020124277
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 5, 2002
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Publication number: 20020112254
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: November 21, 2001
    Publication date: August 15, 2002
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Publication number: 20020056149
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Application
    Filed: November 21, 2001
    Publication date: May 9, 2002
    Applicant: Roslin Institute (Edinburgh)
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Patent number: 6252133
    Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: June 26, 2001
    Assignees: Roslin Institute (Edinburgh), The Minister of Agriculture, Fisheries & Food, Biotechnology & Biological Sciences Research Council
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut
  • Patent number: 6147276
    Abstract: A method of reconstituting a mammalian embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more mammals. The invention is useful in the production of transgenic mammals as well as non-transgenics of high genetic merit.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: November 14, 2000
    Assignees: Roslin Institute (Edinburgh), The Minister of Agriculture, Fisheries & Food, Biotechnology & Biological Sciences Research Council
    Inventors: Keith Henry Stockman Campbell, Ian Wilmut